CD274 and non-small cell lung carcinoma: Other drugs targeting CTLA-4, including an open-label phase II study of NSCLC patients treated with KN046, a recombinant humanized PD-L1/CTLA-4 bispecific antibody, were reported during the 2021 meeting of the American Society of Clinical Oncology (ASCO).